• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Genomics >Systematic identification of dysregulated lncRNAs associated with platinum-based chemotherapy response across 11 cancer types
【24h】

Systematic identification of dysregulated lncRNAs associated with platinum-based chemotherapy response across 11 cancer types

机译：在11种癌症类型中系统鉴定与基于铂的化疗反应相关的失调的LNCRNA

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aberrant expression of long non-coding RNAs (lncRNAs) leads to the development of chemoresistance by regulating a series of biological processes, which is one of the major obstacles in the cancer treatment. This study aimed to identify some key lncRNAs that are associated with platinum-based chemoresistance in multiple cancers. Regulating the expression levels of these lncRNAs can enhance the sensitivity of patients to chemotherapy drugs and improve the therapeutic effect of cancer. By systematically analyzing 648 samples regarding platinum drug response from the Cancer Genome Atlas (TCGA), we have identified 32 dysregulated lncRNAs across 11 cancer types that could affect platinum-based chemotherapy response, of which 78.125% (25/32) were significantly down-regulated in drug-resistant samples. Drug response prediction model that had been constructed based on the expression pattern of these dysregulated lncRNAs could accurately predict the chemotherapy response of tumor patients, and the area under the curve (AUC) was between 0.8034 and 0.9984. In particular, all of these dysregulated lncRNAs that we identified were cancer-specific. They were significantly associated with the survival of tumor patients and could serve as cancer-specific biomarkers for prognosis. In conclusion, this study will contribute to improving the drug resistance of tumor patients during chemotherapy, and it is of real significance for selecting effective chemotherapy drugs and achieving precision medicine.
机译：长期非编码RNA（LNCRNA）的异常表达通过调节一系列生物过程来促进化学渗透度，这是癌症治疗中的主要障碍之一。该研究旨在鉴定一些与多种癌症中铂基化学抑制相关的关键LNCRNA。调节这些LNCRNA的表达水平可以增强患者对化疗药物的敏感性，提高癌症的治疗效果。通过系统地分析来自癌症基因组Atlas（TCGA）的铂药物反应的648个样品，我们已经发现了32种具有可能影响基于铂类化疗反应的11种失呼的LNCRNA，其中78.125％（25/32）显着下降 - 在耐药样品中调节。基于这些失去的LNCRNA的表达模式构建的药物反应预测模型可以准确地预测肿瘤患者的化疗响应，曲线（AUC）下的面积在0.8034和0.9984之间。特别是，我们鉴定的所有这些失去的LNCRNA是癌症特异性的。它们与肿瘤患者的存活率显着相关，并且可以作为癌症特异性生物标志物进行预后。总之，本研究将有助于提高化疗期间肿瘤患者的耐药性，并且对选择有效化疗药物和达到精密药物具有实际意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号